JP2022510303A5 - - Google Patents

Info

Publication number
JP2022510303A5
JP2022510303A5 JP2021531034A JP2021531034A JP2022510303A5 JP 2022510303 A5 JP2022510303 A5 JP 2022510303A5 JP 2021531034 A JP2021531034 A JP 2021531034A JP 2021531034 A JP2021531034 A JP 2021531034A JP 2022510303 A5 JP2022510303 A5 JP 2022510303A5
Authority
JP
Japan
Prior art keywords
composition according
effective amount
empagliflozin
benzofuran
dibromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510303A (ja
JP7528080B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064785 external-priority patent/WO2020118114A1/en
Publication of JP2022510303A publication Critical patent/JP2022510303A/ja
Publication of JP2022510303A5 publication Critical patent/JP2022510303A5/ja
Application granted granted Critical
Publication of JP7528080B2 publication Critical patent/JP7528080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531034A 2018-12-06 2019-12-05 痛風または高尿酸血症を処置または予防するための方法 Active JP7528080B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776251P 2018-12-06 2018-12-06
US62/776,251 2018-12-06
PCT/US2019/064785 WO2020118114A1 (en) 2018-12-06 2019-12-05 Methods for treating or preventing gout or hyperuricemia

Publications (3)

Publication Number Publication Date
JP2022510303A JP2022510303A (ja) 2022-01-26
JP2022510303A5 true JP2022510303A5 (https=) 2022-12-12
JP7528080B2 JP7528080B2 (ja) 2024-08-05

Family

ID=70974386

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531034A Active JP7528080B2 (ja) 2018-12-06 2019-12-05 痛風または高尿酸血症を処置または予防するための方法

Country Status (12)

Country Link
US (1) US12419854B2 (https=)
EP (1) EP3890722A4 (https=)
JP (1) JP7528080B2 (https=)
CN (1) CN113164439A (https=)
AU (1) AU2019392750B2 (https=)
BR (1) BR112021010720A2 (https=)
CA (1) CA3121624A1 (https=)
EA (1) EA202191543A1 (https=)
IL (1) IL283665A (https=)
SG (1) SG11202105743RA (https=)
TW (1) TW202038936A (https=)
WO (1) WO2020118114A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113214198B (zh) 2016-07-18 2022-12-23 广州瑞安博医药科技有限公司 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
US12145917B2 (en) 2018-12-06 2024-11-19 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CN113368032A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 药物组合物、口服固体制剂及其制备方法和用途
US20250066316A1 (en) * 2021-12-02 2025-02-27 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CN118974028A (zh) * 2021-12-30 2024-11-15 广州瑞安博医药科技有限公司 用于治疗痛风或高尿酸血症的化合物的制备

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP2616252B2 (ja) 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
DE19624292A1 (de) 1996-06-18 1998-01-02 Merckle Gmbh Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP1767531A4 (en) 2004-06-10 2011-01-05 Torii Pharmaceutical Co Ltd 6-HYDROXYBENZBROMARONE OR SALTING MEDICAL COMPOSITIONS CONTAINING THEREOF
US20080305169A1 (en) 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
BRPI0809843A2 (pt) 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US8791077B2 (en) 2008-05-22 2014-07-29 Astrazeneca Ab Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
JP5325065B2 (ja) 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
IT1400609B1 (it) * 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
US20150031768A1 (en) 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
US9708388B2 (en) 2012-04-11 2017-07-18 Hoffmann-La Roche Inc. Antibody light chains
KR20210033067A (ko) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
WO2014028668A2 (en) 2012-08-14 2014-02-20 Minerva Biotechnologies Corporation Stem cell enhancing therapeutics
JP2016500367A (ja) 2012-12-05 2016-01-12 デュタリス ゲーエムベーハー デュアルターゲティング
WO2014113407A2 (en) 2013-01-16 2014-07-24 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
JP2016512817A (ja) 2013-03-15 2016-05-09 ヤンセン ファーマシューティカ エヌ.ベー. 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
CN105579037A (zh) 2013-05-31 2016-05-11 武田制药美国有限公司 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
WO2015134467A1 (en) 2014-03-05 2015-09-11 The Trustees Of Princeton University Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks
MX2017001103A (es) 2014-07-31 2017-04-27 Merck Patent Gmbh Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
CN104262305B (zh) 2014-09-16 2016-06-08 东北制药集团股份有限公司 一种苯溴马隆晶型a及其制备方法
CN104311516B (zh) 2014-09-16 2017-01-11 东北制药集团股份有限公司 一种苯溴马隆晶型b及其制备方法
CN113214198B (zh) 2016-07-18 2022-12-23 广州瑞安博医药科技有限公司 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
WO2018090921A1 (zh) 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2018110887A1 (ko) 2016-12-14 2018-06-21 주식회사 엘지화학 헤테로 고리 화합물 및 이를 포함하는 유기 발광 소자
WO2019195118A1 (en) 2018-04-03 2019-10-10 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
US20210338648A1 (en) 2018-10-01 2021-11-04 Astrazeneca Ab Methods and compositions for reducing serum uric acid
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
US12145917B2 (en) 2018-12-06 2024-11-19 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EP3968989A4 (en) 2019-05-14 2022-12-28 Arthrosi Therapeutics, Inc. COMPOUND FOR TREATMENT OF GOUT OR HYPERURICEMIA
CN112952564B (zh) 2019-12-25 2022-04-22 华为数字能源技术有限公司 配电模块及通信电源系统
WO2021252630A1 (en) 2020-06-10 2021-12-16 Arthrosi Therapeutics, Inc. Methods for treating or preventing chronic kidney disease
CN112729156A (zh) 2020-12-24 2021-04-30 上海智能制造功能平台有限公司 一种人体数字化测量装置的数据拼接及系统标定方法
CN114697265A (zh) 2020-12-29 2022-07-01 华为技术服务有限公司 一种报文处理方法及装置
US20250066316A1 (en) 2021-12-02 2025-02-27 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CN118974028A (zh) 2021-12-30 2024-11-15 广州瑞安博医药科技有限公司 用于治疗痛风或高尿酸血症的化合物的制备

Similar Documents

Publication Publication Date Title
JP2022510303A5 (https=)
Pacher et al. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
WO2005082863A3 (en) 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
WO2005070006A3 (en) Nitrosated and/or nitrosylated compounds, compositions and methods of use
MX2009002239A (es) Derivados de 5-(2-furil)-1,3-tiazol util como inhibidores de fosfatidilinositol 3-cinasa.
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
NO20072461L (no) Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme
JP2011504935A5 (https=)
JP2009531281A5 (https=)
JP2019519533A5 (https=)
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
UY37631A (es) Inhibidor de la quinasa reguladora de la señal de apoptosis
NO20091254L (no) Terapeutiske sammensetninger
JP2009520801A5 (https=)
UY31431A1 (es) Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap)
NO20072934L (no) Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt
JP2021522247A5 (https=)
JP2024028337A5 (https=)
JPWO2023195530A5 (https=)
JP2022533958A5 (https=)
EA201990664A1 (ru) Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма
JP2020529995A5 (https=)
Patel et al. Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy